Drug Targeting Organ-Specific Strategies
Drug Targeting Organ-Specific Strategies
Drug Targeting Organ-Specific Strategies
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
378 Index<br />
c<br />
cancer, see tumor<br />
carbohydrate modifications 100, 113, 127,<br />
182, 219, 280<br />
carrier 2, 275, 276<br />
see also<br />
– cellular carriers<br />
– liposomes<br />
– lipoproteins<br />
– microspheres<br />
– antibodies, monoclonal<br />
– micelles, polymeric<br />
– proteins, modified (plasma)<br />
– nanoparticles<br />
– polymers, soluble<br />
carrier development 275<br />
cationized albumin, see proteins, modified<br />
(plasma)<br />
cellular carriers 7<br />
central nervous system, see brain<br />
chimeric peptides 41, 43<br />
cirrhosis, see fibrosis<br />
clinical applications 10<br />
– liposomes 11, 12, 114, 225<br />
– antibodies 11, 14, 15, 221, 268<br />
– polymers 13, 15, 225<br />
– proteins, modified (plasma) 15, 114<br />
coaguligand, see blood coagulation,<br />
targeted induction of<br />
COER-24 162, 166<br />
colon 157<br />
– animal models, see animal models<br />
(of disease)<br />
– inflammation 159<br />
– microflora 157, 159<br />
– motility 158<br />
– pH 158, 159<br />
– transit time 158<br />
colonic delivery 157, 158<br />
– absorption 161<br />
– animal models (of disease), see animal<br />
models<br />
– degradable coatings 164<br />
– drug delivery index (DDI) 163<br />
– enteric coatings 161<br />
– enzyme controlled 161, 163<br />
– hydrogels 165<br />
– matrices 165<br />
– pH controlled 160, 161<br />
– pressure controlled 161, 167<br />
– pro-drug 163<br />
– time controlled 161, 166<br />
– visualization 168<br />
compartmental models 329<br />
conjugation techniques<br />
– chemical 43, 111, 112, 285<br />
– using recombinant DNA techniques 43,<br />
292<br />
COPD 53, 77<br />
corticosteroids<br />
– in inflammation 183<br />
– in inflammatory bowel disease (IBD)<br />
160<br />
– in liver fibrosis 99, 104, 112<br />
– in pulmonary diseases 53, 66<br />
cystic fibrosis 53, 83<br />
cytochrome-c 140<br />
cytokines 17, 40, 92pp, 104, 124, 172,<br />
175pp, 210, 224, 298pp, 323, 372<br />
– in angiogenesis 235, 237<br />
cytotoxins 298, 300, 243, 245<br />
d<br />
diabodies, see antibodies<br />
dosing schedules 368<br />
drug delivery index 163<br />
drug delivery to the target site 353<br />
drug release<br />
– at the target site 353<br />
– at non-target sites 355<br />
– in colonic delivery 160<br />
– in renal targeting 136, 140<br />
– extracellular release 291<br />
– lysosomal release 289<br />
drug removal from the target site 354<br />
drug targeting<br />
– active targeting 8, 371<br />
– passive targeting 8, 371<br />
– pharmacokinetics, PK/PD modelling<br />
333, 351, 361, 364, 367<br />
– receptor based 372, 373<br />
– in drug innovation 375<br />
drug targeting index 355, 358, 362<br />
drugs 192, 283<br />
– see also corticosteroids and NSAIDs<br />
– anti-angiogenic 186, 251<br />
– antibiotics 83, 344<br />
– anti-HIV 267, 269<br />
– anti-inflammatory 103, 160, 182<br />
– cytostatic agents 48, 204, 214, 344<br />
– formulations for pulmonary delivery 67<br />
– JAK/STAT inhibitors 183<br />
– neuroactive drugs 24, 35<br />
– metabolism 310, 315<br />
–NFκB inhibitors 182<br />
– protein binding 337<br />
– selection for conjugation to carrier 283<br />
– selection for effective targeting 361, 363<br />
– for liver fibrosis 98, 103, 105<br />
– for pulmonary diseases 53<br />
– in renal targeting 137, 149<br />
– pharmacokinetics 333<br />
– transport 28, 35, 318, 319, 336, 340<br />
dry powder formulations 68<br />
dual targeting strategies 102, 250, 365
Change language